Skip to main content
SpringerLink
Log in

Natural History of Nonalcoholic Fatty Liver Disease

  • Chapter
  • First Online:
Essentials of Non-Alcoholic Fatty Liver Disease

  • 369 Accesses

Abstract

The most prevalent chronic liver disease is nonalcoholic fatty liver disease (NAFLD), being associated with the epidemics of obesity and metabolic syndrome (MetS). The prognosis of NAFLD varies; however, it can be relatively predicted based on the presence or absence of histological liver injury. The NAFLD spectrum includes simple steatosis, also known as nonalcoholic fatty liver (NAFL); steatosis with necro-inflammatory changes, known as nonalcoholic steatohepatitis (NASH); NASH-related cirrhosis; and hepatocellular cancer. The most significant histological predictor of hepatic and non-hepatic related mortality, according to recently available data, is liver fibrosis rather than NASH per se. Several risk factors were found to influence the progression of NAFLD including MetS and its components, as well as genetics and environmental factors. Beyond the liver, where cardiovascular disease and cancer are two additional significant mortality causes, NAFLD is crucial for overall survival.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sporea I, Popescu A, Dumitrașcu D, Brisc C, Nedelcu L, Trifan A, et al. Nonalcoholic fatty liver disease: status quo. J Gastrointestin Liver Dis. 2018;27(4):439–48. https://doi.org/10.15403/jgld.2014.1121.274.quo.

    Article  PubMed  Google Scholar 

  2. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–23. https://doi.org/10.1002/hep.25762.

    Article  PubMed  Google Scholar 

  3. Ando Y, Jou JH. Nonalcoholic fatty liver disease and recent guideline updates. Clin Liver Dis. 2021;17(1):23–8. https://doi.org/10.1002/cld.1045.

    Article  Google Scholar 

  4. Mikolasevic I, Filipec-Kanizaj T, Mijic M, Jakopcic I, Milic S, Hrstic I, et al. Nonalcoholic fatty liver disease and liver transplantation—where do we stand? World J Gastroenterol. 2018;24(14):1491–506. https://doi.org/10.3748/wjg.v24.i14.1491.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Younossi ZM, Marchesini G, Pinto-Cortez H, Petta S. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver Transplantation. Transplantation. 2019;103(1):22–7. https://doi.org/10.1097/tp.0000000000002484.

    Article  PubMed  Google Scholar 

  6. (NCD-RisC) NRFC. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016;387(10026):1377–96. https://doi.org/10.1016/s0140-6736(16)30054-x.

    Article  Google Scholar 

  7. Mantovani A, Petracca G, Beatrice G, Csermely A, Tilg H, Byrne CD, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut. 2021;71(4):gutjnl-2021-324191. https://doi.org/10.1136/gutjnl-2021-324191.

    Article  Google Scholar 

  8. Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022;23(4):521–30. https://doi.org/10.1016/S1470-2045(22)00078-X.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Ismaiel A, Dumitrascu DL. Cardiovascular risk in fatty liver disease: the liver-heart axis-literature review. Front Med (Lausanne). 2019;6:202. https://doi.org/10.3389/fmed.2019.00202.

    Article  PubMed  Google Scholar 

  10. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11(1):74–80.

    Article  PubMed  Google Scholar 

  11. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29(3):664–9. https://doi.org/10.1002/hep.510290347.

    Article  CAS  PubMed  Google Scholar 

  12. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology. 2000;32(4 Pt 1):689–92. https://doi.org/10.1053/jhep.2000.17894.

    Article  CAS  PubMed  Google Scholar 

  13. Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016;65(8):1017–25. https://doi.org/10.1016/j.metabol.2016.01.012.

    Article  CAS  PubMed  Google Scholar 

  14. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413–9. https://doi.org/10.1016/s0016-5085(99)70506-8.

    Article  CAS  PubMed  Google Scholar 

  15. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57. https://doi.org/10.1002/hep.29367.

    Article  PubMed  Google Scholar 

  16. Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020; https://doi.org/10.1053/j.gastro.2019.11.312.

  17. Eslam M, Newsome PN, Anstee QM, Targher G, Gomez MR, Zelber-Sagi S, et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020; https://doi.org/10.1016/j.jhep.2020.03.039.

  18. Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7(5):388–90. https://doi.org/10.1016/S2468-1253(22)00062-0.

    Article  PubMed  Google Scholar 

  19. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis. 2001;21(1):17–26. https://doi.org/10.1055/s-2001-12926.

    Article  CAS  PubMed  Google Scholar 

  20. Goh GB, McCullough AJ. Natural history of nonalcoholic fatty liver disease. Dig Dis Sci. 2016;61(5):1226–33. https://doi.org/10.1007/s10620-016-4095-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. https://doi.org/10.1002/hep.28431.

    Article  PubMed  Google Scholar 

  22. (EASL). EAftSotL, (EASD). EAftSoD, (EASO). EAftSoO. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402. https://doi.org/10.1016/j.jhep.2015.11.004.

    Article  Google Scholar 

  23. Caldwell S, Argo C. The natural history of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):162–8. https://doi.org/10.1159/000282081.

    Article  CAS  PubMed  Google Scholar 

  24. Dumitrascu DL, Neuman MG. Non-alcoholic fatty liver disease: an update on diagnosis. Clujul Med (1957). 2018;91(2):147–50. https://doi.org/10.15386/cjmed-993.

    Article  Google Scholar 

  25. Filipović B, Forbes A, Tepeš B, Dumitraşcu DL. Nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol. 2018;2018:2097435. https://doi.org/10.1155/2018/2097435.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Ismaiel A, Dumitrascu DL. How to reduce cardiovascular risk in nonalcoholic fatty liver disease. Am J Ther. 2020; Publish Ahead of Print.; https://doi.org/10.1097/mjt.0000000000001174.

  27. Ismaiel A, Popa S-L, Dumitrascu DL. Acute coronary syndromes and nonalcoholic fatty liver disease: “Un Affaire de Coeur”. Can J Gastroenterol Hepatol. 2020;2020:8825615. https://doi.org/10.1155/2020/8825615.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Ismaiel A, Colosi HA, Rusu F, Dumitrascu DL. Cardiac arrhythmias and electrocardiogram modifications in non-alcoholic fatty liver disease. a systematic review. J Gastrointestin Liver Dis. 2019;28(4):483–93. https://doi.org/10.15403/jgld-344.

    Article  PubMed  Google Scholar 

  29. Mantovani A, Petracca G, Beatrice G, Csermely A, Tilg H, Byrne CD, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut. 2022;71(4):778–88. https://doi.org/10.1136/gutjnl-2021-324191.

    Article  PubMed  Google Scholar 

  30. Liu SS, Ma XF, Zhao J, Du SX, Zhang J, Dong MZ, et al. Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis. Lipids Health Dis. 2020;19(1):118. https://doi.org/10.1186/s12944-020-01288-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Orci LA, Sanduzzi-Zamparelli M, Caballol B, Sapena V, Colucci N, Torres F, et al. Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Clin Gastroenterol Hepatol. 2022;20(2):283–92.e10. https://doi.org/10.1016/j.cgh.2021.05.002.

    Article  PubMed  Google Scholar 

  32. Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903–13. https://doi.org/10.1016/s2468-1253(21)00308-3.

    Article  PubMed  Google Scholar 

  33. Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005;43(3):508–14. https://doi.org/10.1016/j.jhep.2005.02.042.

    Article  PubMed  Google Scholar 

  34. Amarapurkar D, Kamani P, Patel N, Gupte P, Kumar P, Agal S, et al. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol. 2007;6(3):161–3.

    Article  PubMed  Google Scholar 

  35. Li H, Wang YJ, Tan K, Zeng L, Liu L, Liu FJ, et al. Prevalence and risk factors of fatty liver disease in Chengdu, Southwest China. Hepatobiliary Pancreat Dis Int. 2009;8(4):377–82.

    PubMed  Google Scholar 

  36. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol. 2006;21(1 Pt 1):138–43. https://doi.org/10.1111/j.1440-1746.2005.04086.x.

    Article  PubMed  Google Scholar 

  37. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008;49(4):608–12. https://doi.org/10.1016/j.jhep.2008.06.018.

    Article  PubMed  Google Scholar 

  38. Hashimoto E, Yatsuji S, Kaneda H, Yoshioka Y, Taniai M, Tokushige K, et al. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res. 2005;33(2):72–6. https://doi.org/10.1016/j.hepres.2005.09.007.

    Article  PubMed  Google Scholar 

  39. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113–21.

    Article  PubMed  Google Scholar 

  40. Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, Rafiq N, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(11):1224-9, 9.e1-2. https://doi.org/10.1016/j.cgh.2009.06.007.

    Article  CAS  PubMed  Google Scholar 

  41. Tarantino G, Conca P, Riccio A, Tarantino M, Di Minno MN, Chianese D, et al. Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? J Transl Med. 2008;6:72. https://doi.org/10.1186/1479-5876-6-72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51(6):1972–8. https://doi.org/10.1002/hep.23527.

    Article  PubMed  Google Scholar 

  43. Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. 2009;44(Suppl 19):89–95. https://doi.org/10.1007/s00535-008-2262-x.

    Article  PubMed  Google Scholar 

  44. Liew PL, Lee WJ, Wang W, Lee YC, Chen WY, Fang CL, et al. Fatty liver disease: predictors of nonalcoholic steatohepatitis and gallbladder disease in morbid obesity. Obes Surg. 2008;18(7):847–53. https://doi.org/10.1007/s11695-007-9355-0.

    Article  PubMed  Google Scholar 

  45. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–654.e1-9; quiz e39-40. https://doi.org/10.1016/j.cgh.2014.04.014.

    Article  PubMed  Google Scholar 

  46. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–85. https://doi.org/10.1111/j.1365-2036.2011.04724.x.

    Article  CAS  PubMed  Google Scholar 

  47. Singh SP, Nayak S, Swain M, Rout N, Mallik RN, Agrawal O, et al. Prevalence of nonalcoholic fatty liver disease in coastal eastern India: a preliminary ultrasonographic survey. Trop Gastroenterol. 2004;25(2):76–9.

    PubMed  Google Scholar 

  48. Omagari K, Kadokawa Y, Masuda J, Egawa I, Sawa T, Hazama H, et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol. 2002;17(10):1098–105. https://doi.org/10.1046/j.1440-1746.2002.02846.x.

    Article  PubMed  Google Scholar 

  49. Jamali R, Khonsari M, Merat S, Khoshnia M, Jafari E, Bahram Kalhori A, et al. Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes. World J Gastroenterol. 2008;14(18):2867–71. https://doi.org/10.3748/wjg.14.2867.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology. 2001;121(3):710–23. https://doi.org/10.1053/gast.2001.27126.

    Article  CAS  PubMed  Google Scholar 

  51. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143(10):722–8. https://doi.org/10.7326/0003-4819-143-10-200511150-00009.

    Article  CAS  PubMed  Google Scholar 

  52. Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007;13(10):1579–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Chen ZW, Chen LY, Dai HL, Chen JH, Fang LZ. Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J Zhejiang Univ Sci B. 2008;9(8):616–22. https://doi.org/10.1631/jzus.B0720016.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Kallwitz ER, Kumar M, Aggarwal R, Berger R, Layden-Almer J, Gupta N, et al. Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. Dig Dis Sci. 2008;53(5):1358–63. https://doi.org/10.1007/s10620-008-0234-x.

    Article  PubMed  Google Scholar 

  55. Papatheodoridis GV, Goulis J, Christodoulou D, Manolakopoulos S, Raptopoulou M, Andrioti E, et al. High prevalence of elevated liver enzymes in blood donors: associations with male gender and central adiposity. Eur J Gastroenterol Hepatol. 2007;19(4):281–7. https://doi.org/10.1097/MEG.0b013e328011438b.

    Article  CAS  PubMed  Google Scholar 

  56. Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg. 2005;15(3):310–5. https://doi.org/10.1381/0960892053576820.

    Article  PubMed  Google Scholar 

  57. Sorrentino P, Tarantino G, Conca P, Perrella A, Terracciano ML, Vecchione R, et al. Silent non-alcoholic fatty liver disease-a clinical-histological study. J Hepatol. 2004;41(5):751–7. https://doi.org/10.1016/j.jhep.2004.07.010.

    Article  CAS  PubMed  Google Scholar 

  58. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124–31. https://doi.org/10.1053/j.gastro.2010.09.038.

    Article  PubMed  Google Scholar 

  59. Wagenknecht LE, Scherzinger AL, Stamm ER, Hanley AJ, Norris JM, Chen YD, et al. Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort. Obesity (Silver Spring, MD). 2009;17(6):1240–6. https://doi.org/10.1038/oby.2009.4.

    Article  CAS  PubMed  Google Scholar 

  60. Lomonaco R, Ortiz-Lopez C, Orsak B, Finch J, Webb A, Bril F, et al. Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology. 2011;54(3):837–45. https://doi.org/10.1002/hep.24483.

    Article  PubMed  Google Scholar 

  61. Mohanty SR, Troy TN, Huo D, O'Brien BL, Jensen DM, Hart J. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol. 2009;50(4):797–804. https://doi.org/10.1016/j.jhep.2008.11.017.

    Article  PubMed  Google Scholar 

  62. Solga SF, Clark JM, Alkhuraishi AR, Torbenson M, Tabesh A, Schweitzer M, et al. Race and comorbid factors predict nonalcoholic fatty liver disease histopathology in severely obese patients. Surg Obes Relat Dis. 2005;1(1):6–11. https://doi.org/10.1016/j.soard.2004.12.006.

    Article  PubMed  Google Scholar 

  63. Schwimmer JB, Celedon MA, Lavine JE, Salem R, Campbell N, Schork NJ, et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology. 2009;136(5):1585–92. https://doi.org/10.1053/j.gastro.2009.01.050.

    Article  PubMed  Google Scholar 

  64. Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med. 2000;108(1):9–13. https://doi.org/10.1016/s0002-9343(99)00315-0.

    Article  CAS  PubMed  Google Scholar 

  65. Eslam M, George J. Genetic and epigenetic mechanisms of NASH. Hepatol Int. 2016;10(3):394–406. https://doi.org/10.1007/s12072-015-9689-y.

    Article  PubMed  Google Scholar 

  66. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol. 2018;68(2):268–79. https://doi.org/10.1016/j.jhep.2017.09.003.

    Article  CAS  PubMed  Google Scholar 

  67. Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014;5:4309. https://doi.org/10.1038/ncomms5309.

    Article  CAS  PubMed  Google Scholar 

  68. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461–5. https://doi.org/10.1038/ng.257.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Xiang H, Wu Z, Wang J, Wu T. Research progress, challenges and perspectives on PNPLA3 and its variants in liver diseases. J Cancer. 2021;12(19):5929–37. https://doi.org/10.7150/jca.57951.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53(6):1883–94. https://doi.org/10.1002/hep.24283.

    Article  CAS  PubMed  Google Scholar 

  71. He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem. 2010;285(9):6706–15. https://doi.org/10.1074/jbc.M109.064501.

    Article  CAS  PubMed  Google Scholar 

  72. Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016;17(5) https://doi.org/10.3390/ijms17050774.

  73. Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol. 2016;65(2):425–43. https://doi.org/10.1016/j.jhep.2016.04.005.

    Article  CAS  PubMed  Google Scholar 

  74. Chandrasekharan K, Alazawi W. Genetics of non-alcoholic fatty liver and cardiovascular disease: implications for therapy? Front Pharmacol. 2020;10:1413. https://doi.org/10.3389/fphar.2019.01413.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Ismaiel A, Dumitrascu DL. Genetic predisposition in metabolic-dysfunction-associated fatty liver disease and cardiovascular outcomes-systematic review. Eur J Clin Invest. 2020;50(10):1–14. https://doi.org/10.1111/eci.13331.

    Article  Google Scholar 

  76. Teo K, Abeysekera KWM, Adams L, Aigner E, Anstee QM, Banales JM, et al. rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: a meta-analysis. J Hepatol. 2021;74(1):20–30. https://doi.org/10.1016/j.jhep.2020.08.027.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52(3):913–24. https://doi.org/10.1002/hep.23784.

    Article  CAS  PubMed  Google Scholar 

  78. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011;7(3):e1001324. https://doi.org/10.1371/journal.pgen.1001324.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Yang Z, Wen J, Tao X, Lu B, Du Y, Wang M, et al. Genetic variation in the GCKR gene is associated with non-alcoholic fatty liver disease in Chinese people. Mol Biol Rep. 2011;38(2):1145–50. https://doi.org/10.1007/s11033-010-0212-1.

    Article  CAS  PubMed  Google Scholar 

  80. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59(7):969–74. https://doi.org/10.1136/gut.2009.205088.

    Article  PubMed  Google Scholar 

  81. Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013;59(3):550–6. https://doi.org/10.1016/j.jhep.2013.04.027.

    Article  CAS  PubMed  Google Scholar 

  82. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42(1):132–8. https://doi.org/10.1016/j.jhep.2004.09.012.

    Article  PubMed  Google Scholar 

  83. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29(1):113–9. https://doi.org/10.1111/j.1478-3231.2008.01718.x.

    Article  CAS  PubMed  Google Scholar 

  84. Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut. 2010;59(10):1410–5. https://doi.org/10.1136/gut.2010.213553.

    Article  PubMed  Google Scholar 

  85. Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132(2):112–7. https://doi.org/10.7326/0003-4819-132-2-200001180-00004.

    Article  CAS  PubMed  Google Scholar 

  86. Boza C, Riquelme A, Ibañez L, Duarte I, Norero E, Viviani P, et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg. 2005;15(8):1148–53. https://doi.org/10.1381/0960892055002347.

    Article  PubMed  Google Scholar 

  87. Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology. 2004;40(2):475–83. https://doi.org/10.1002/hep.20323.

    Article  PubMed  Google Scholar 

  88. Dolce CJ, Russo M, Keller JE, Buckingham J, Norton HJ, Heniford BT, et al. Does liver appearance predict histopathologic findings: prospective analysis of routine liver biopsies during bariatric surgery. Surg Obes Relat Dis. 2009;5(3):323–8. https://doi.org/10.1016/j.soard.2008.12.008.

    Article  PubMed  Google Scholar 

  89. Beymer C, Kowdley KV, Larson A, Edmonson P, Dellinger EP, Flum DR. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg. 2003;138(11):1240–4. https://doi.org/10.1001/archsurg.138.11.1240.

    Article  PubMed  Google Scholar 

  90. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007;102(2):399–408. https://doi.org/10.1111/j.1572-0241.2006.01041.x.

    Article  CAS  PubMed  Google Scholar 

  91. Harnois F, Msika S, Sabaté JM, Mechler C, Jouet P, Barge J, et al. Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery. Obes Surg. 2006;16(2):183–8. https://doi.org/10.1381/096089206775565122.

    Article  PubMed  Google Scholar 

  92. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45(4):600–6. https://doi.org/10.1016/j.jhep.2006.06.013.

    Article  PubMed  Google Scholar 

  93. Colicchio P, Tarantino G, del Genio F, Sorrentino P, Saldalamacchia G, Finelli C, et al. Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. Ann Nutr Metab. 2005;49(5):289–95. https://doi.org/10.1159/000087295.

    Article  CAS  PubMed  Google Scholar 

  94. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43(2 Suppl 1):S99–s112. https://doi.org/10.1002/hep.20973.

    Article  CAS  PubMed  Google Scholar 

  95. Baranova A, Tran TP, Birerdinc A, Younossi ZM. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;33(7):801–14. https://doi.org/10.1111/j.1365-2036.2011.04579.x.

    Article  CAS  PubMed  Google Scholar 

  96. Romanowski MD, Parolin MB, Freitas AC, Piazza MJ, Basso J, Urbanetz AA. Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome. Arq Gastroenterol. 2015;52(2):117–23. https://doi.org/10.1590/s0004-28032015000200008.

    Article  PubMed  Google Scholar 

  97. Kelley CE, Brown AJ, Diehl AM, Setji TL. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World J Gastroenterol. 2014;20(39):14172–84. https://doi.org/10.3748/wjg.v20.i39.14172.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Hossain N, Stepanova M, Afendy A, Nader F, Younossi Y, Rafiq N, et al. Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS). Scand J Gastroenterol. 2011;46(4):479–84. https://doi.org/10.3109/00365521.2010.539251.

    Article  PubMed  Google Scholar 

  99. Teli MR, James OFW, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22(6):1714–9. https://doi.org/10.1002/hep.1840220616.

    Article  CAS  PubMed  Google Scholar 

  100. Adams LA, Ratziu V. Non-alcoholic fatty liver—perhaps not so benign. J Hepatol. 2015;62(5):1002–4. https://doi.org/10.1016/j.jhep.2015.02.005.

    Article  PubMed  Google Scholar 

  101. De A, Duseja A. Natural history of simple steatosis or nonalcoholic fatty liver. J Clin Exp Hepatol. 2020;10(3):255–62. https://doi.org/10.1016/j.jceh.2019.09.005.

    Article  PubMed  Google Scholar 

  102. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. J Hepatol. 2015;62(5):1148–55. https://doi.org/10.1016/j.jhep.2014.11.034.

    Article  PubMed  Google Scholar 

  103. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43(8):617–49. https://doi.org/10.3109/07853890.2010.518623.

    Article  PubMed  Google Scholar 

  104. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009;49(3):851–9. https://doi.org/10.1002/hep.22734.

    Article  PubMed  Google Scholar 

  105. Kawada N, Imanaka K, Kawaguchi T, Tamai C, Ishihara R, Matsunaga T, et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol. 2009;44(12):1190–4. https://doi.org/10.1007/s00535-009-0112-0.

    Article  PubMed  Google Scholar 

  106. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–54. https://doi.org/10.1002/hep.21496.

    Article  CAS  PubMed  Google Scholar 

  107. Ballestri S, Nascimbeni F, Romagnoli D, Lonardo A. The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res. 2016;46(11):1074–87. https://doi.org/10.1111/hepr.12656.

    Article  CAS  PubMed  Google Scholar 

  108. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121(1):91–100. https://doi.org/10.1053/gast.2001.25540.

    Article  CAS  PubMed  Google Scholar 

  109. Carulli L, Canedi I, Rondinella S, Lombardini S, Ganazzi D, Fargion S, et al. Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. Dig Liver Dis. 2009;41(11):823–8. https://doi.org/10.1016/j.dld.2009.03.005.

    Article  CAS  PubMed  Google Scholar 

  110. Petta S, Camma C, Cabibi D, Di Marco V, Craxi A. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;34(7):757–66. https://doi.org/10.1111/j.1365-2036.2011.04788.x.

    Article  CAS  PubMed  Google Scholar 

  111. Carulli L, Ballestri S, Lonardo A, Lami F, Violi E, Losi L, et al. Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels? Intern Emerg Med. 2013;8(4):297–305. https://doi.org/10.1007/s11739-011-0609-4.

    Article  PubMed  Google Scholar 

  112. Dasarathy J, Periyalwar P, Allampati S, Bhinder V, Hawkins C, Brandt P, et al. Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease. Liver Int. 2014;34(6):e118–27. https://doi.org/10.1111/liv.12312.

    Article  CAS  PubMed  Google Scholar 

  113. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009;51(2):371–9. https://doi.org/10.1016/j.jhep.2009.03.019.

    Article  CAS  PubMed  Google Scholar 

  114. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–97.e10. https://doi.org/10.1053/j.gastro.2015.04.043.

    Article  PubMed  Google Scholar 

  115. Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–54. https://doi.org/10.1002/hep.27368.

    Article  CAS  PubMed  Google Scholar 

  116. Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab. 2015;100(6):2231–8. https://doi.org/10.1210/jc.2015-1966.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Ratziu V, Cadranel JF, Serfaty L, Denis J, Renou C, Delassalle P, et al. A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France. J Hepatol. 2012;57(2):376–83. https://doi.org/10.1016/j.jhep.2012.03.019.

    Article  PubMed  Google Scholar 

  118. Younossi ZM, Henry L. Economic and quality-of-life implications of non-alcoholic fatty liver disease. Pharmacoeconomics. 2015;33(12):1245–53. https://doi.org/10.1007/s40273-015-0316-5.

    Article  PubMed  Google Scholar 

  119. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8(3):521–33., viii. https://doi.org/10.1016/j.cld.2004.04.004.

    Article  PubMed  Google Scholar 

  120. Önnerhag K, Nilsson PM, Lindgren S. Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD. Scand J Gastroenterol. 2014;49(9):1111–8. https://doi.org/10.3109/00365521.2014.934911.

    Article  PubMed  Google Scholar 

  121. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865–73. https://doi.org/10.1002/hep.21327.

    Article  CAS  PubMed  Google Scholar 

  122. Koehler EM, Plompen EP, Schouten JN, Hansen BE, Darwish Murad S, Taimr P, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study. Hepatology. 2016;63(1):138–47. https://doi.org/10.1002/hep.27981.

    Article  CAS  PubMed  Google Scholar 

  123. You SC, Kim KJ, Kim SU, Kim BK, Park JY, Kim DY, et al. Factors associated with significant liver fibrosis assessed using transient elastography in general population. World J Gastroenterol. 2015;21(4):1158–66. https://doi.org/10.3748/wjg.v21.i4.1158.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Roulot D, Czernichow S, Le Clésiau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol. 2008;48(4):606–13. https://doi.org/10.1016/j.jhep.2007.11.020.

    Article  PubMed  Google Scholar 

  125. Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, Byth K, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003;38(2):420–7. https://doi.org/10.1053/jhep.2003.50320.

    Article  PubMed  Google Scholar 

  126. Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006;43(4):682–9. https://doi.org/10.1002/hep.21103.

    Article  PubMed  Google Scholar 

  127. Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011;54(4):1208–16. https://doi.org/10.1002/hep.24491.

    Article  PubMed  Google Scholar 

  128. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123(1):134–40. https://doi.org/10.1053/gast.2002.34168.

    Article  PubMed  Google Scholar 

  129. Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl. 2001;7(9):797–801. https://doi.org/10.1053/jlts.2001.24644.

    Article  CAS  PubMed  Google Scholar 

  130. McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015;19(2):223–38. https://doi.org/10.1016/j.cld.2015.01.001.

    Article  PubMed  PubMed Central  Google Scholar 

  131. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012;56(6):1384–91. https://doi.org/10.1016/j.jhep.2011.10.027.

    Article  PubMed  Google Scholar 

  132. Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014;60(1):110–7. https://doi.org/10.1016/j.jhep.2013.08.011.

    Article  PubMed  Google Scholar 

  133. Lindenmeyer CC, McCullough AJ. The natural history of nonalcoholic fatty liver disease—an evolving view. Clin Liver Dis. 2018;22(1):11–21. https://doi.org/10.1016/j.cld.2017.08.003.

    Article  PubMed  PubMed Central  Google Scholar 

  134. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140(2):197–208. https://doi.org/10.1016/j.cell.2009.12.052.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Zámbó V, Simon-Szabó L, Szelényi P, Kereszturi E, Bánhegyi G, Csala M. Lipotoxicity in the liver. World J Hepatol. 2013;5(10):550–7. https://doi.org/10.4254/wjh.v5.i10.550.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Duan XF, Tang P, Li Q, Yu ZT. Obesity, adipokines and hepatocellular carcinoma. Int J Cancer. 2013;133(8):1776–83. https://doi.org/10.1002/ijc.28105.

    Article  CAS  PubMed  Google Scholar 

  137. Oliveira CP, Stefano JT. Genetic polymorphisms and oxidative stress in non-alcoholic steatohepatitis (NASH): A mini review. Clin Res Hepatol Gastroenterol. 2015;39(Suppl 1):S35–40. https://doi.org/10.1016/j.clinre.2015.05.014.

    Article  CAS  PubMed  Google Scholar 

  138. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482(7384):179–85. https://doi.org/10.1038/nature10809.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Mittal S, Sada YH, El-Serag HB, Kanwal F, Duan Z, Temple S, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015;13(3):594–601.e1. https://doi.org/10.1016/j.cgh.2014.08.013.

    Article  PubMed  Google Scholar 

  140. Giannini EG, Marabotto E, Savarino V, Trevisani F, di Nolfo MA, Del Poggio P, et al. Hepatocellular carcinoma in patients with cryptogenic cirrhosis. Clin Gastroenterol Hepatol. 2009;7(5):580–5. https://doi.org/10.1016/j.cgh.2009.01.001.

    Article  PubMed  Google Scholar 

  141. Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62(6):1723–30. https://doi.org/10.1002/hep.28123.

    Article  CAS  PubMed  Google Scholar 

  142. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10(12):1342–59.e2. https://doi.org/10.1016/j.cgh.2012.10.001.

    Article  PubMed  PubMed Central  Google Scholar 

  143. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol. 2009;24(2):248–54. https://doi.org/10.1111/j.1440-1746.2008.05640.x.

    Article  CAS  PubMed  Google Scholar 

  144. Thomas JA, Kendall BJ, Dalais C, Macdonald GA, Thrift AP. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Eur J Cancer. 2022;173:250–62. https://doi.org/10.1016/j.ejca.2022.06.051.

    Article  CAS  PubMed  Google Scholar 

  145. Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol. 2012;107(2):253–61. https://doi.org/10.1038/ajg.2011.327.

    Article  CAS  PubMed  Google Scholar 

  146. Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2011;128(10):2436–43. https://doi.org/10.1002/ijc.25797.

    Article  CAS  PubMed  Google Scholar 

  147. Mishra A, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. J Clin Exp Hepatol. 2012;2(2):135–44. https://doi.org/10.1016/S0973-6883(12)60102-9.

    Article  PubMed  PubMed Central  Google Scholar 

  148. Bhagat V, Mindikoglu AL, Nudo CG, Schiff ER, Tzakis A, Regev A. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl. 2009;15(12):1814–20. https://doi.org/10.1002/lt.21927.

    Article  PubMed  Google Scholar 

  149. Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl. 2010;16(4):431–9. https://doi.org/10.1002/lt.22004.

    Article  PubMed  Google Scholar 

  150. Malik SM, deVera ME, Fontes P, Shaikh O, Ahmad J. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant. 2009;9(4):782–93. https://doi.org/10.1111/j.1600-6143.2009.02590.x.

    Article  CAS  PubMed  Google Scholar 

  151. Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation. 1996;62(12):1802–5. https://doi.org/10.1097/00007890-199612270-00021.

    Article  CAS  PubMed  Google Scholar 

  152. Malik SM, Devera ME, Fontes P, Shaikh O, Sasatomi E, Ahmad J. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transpl. 2009;15(12):1843–51. https://doi.org/10.1002/lt.21943.

    Article  PubMed  Google Scholar 

  153. Saeed N, Glass L, Sharma P, Shannon C, Sonnenday CJ, Tincopa MA. Incidence and risks for nonalcoholic fatty liver disease and steatohepatitis post-liver transplant: systematic review and meta-analysis. Transplantation. 2019;103(11):e345–e54. https://doi.org/10.1097/tp.0000000000002916.

    Article  CAS  PubMed  Google Scholar 

  154. Losurdo G, Castellaneta A, Rendina M, Carparelli S, Leandro G, Di Leo A. Systematic review with meta-analysis: de novo non-alcoholic fatty liver disease in liver-transplanted patients. Aliment Pharmacol Ther. 2018;47(6):704–14. https://doi.org/10.1111/apt.14521.

    Article  CAS  PubMed  Google Scholar 

  155. Minich A, Arisar FAQ, N-uS S, Herman L, Azhie A, Orchanian-Cheff A, et al. Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: a systematic review and meta-analysis. eClinicalMedicine. 2022:50. https://doi.org/10.1016/j.eclinm.2022.101534.

  156. Lee Y, Doumouras AG, Yu J, Brar K, Banfield L, Gmora S, et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(6):1040–60 e11. https://doi.org/10.1016/j.cgh.2018.10.017.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 2nd Department of Internal Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania

    Abdulrahman Ismaiel & Dan L. Dumitrascu

  2. Department of Biomedical Sciences and Human Oncology, Clinica Medica “A. Murri”, University of Bari “Aldo Moro” Medical School, Bari, Italy

    Piero Portincasa

Authors
  1. Abdulrahman Ismaiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Piero Portincasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dan L. Dumitrascu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dan L. Dumitrascu .

Editor information

Editors and Affiliations

  1. Department of Gastroenterology and Hepatology, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania

    Anca Trifan

  2. Department of Gastroenterology and Hepatology, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania

    Carol Stanciu

  3. Department of Gastroenterology and Hepatology, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania

    Cristina Muzica

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ismaiel, A., Portincasa, P., Dumitrascu, D.L. (2023). Natural History of Nonalcoholic Fatty Liver Disease. In: Trifan, A., Stanciu, C., Muzica, C. (eds) Essentials of Non-Alcoholic Fatty Liver Disease. Springer, Cham. https://doi.org/10.1007/978-3-031-33548-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-33548-8_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-33547-1

  • Online ISBN: 978-3-031-33548-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation